Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company
pioneering transformative medicines that target the endocannabinoid
system, today announced the publication of two abstracts at the
European League Against Rheumatism (EULAR) 2021 Virtual Congress
that will be taking place June 2-5, 2021.
Details of the presentations are as follows:
Presentation
Title: Phase 3 Trial of Lenabasum, a CB2
Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis
(dcSSc)Session: Progress in myositis and
scleroderma research - IDate: Thursday, June
3, 2021Presentation Time: 10:25 a.m. - 10:32
a.m. CEST (4:25 a.m. – 4:32 a.m. EDT)Presenter:
Robert Spiera, M.D., Director of the Scleroderma, Vasculitis, and
Myositis Program at the Hospital for Special Surgery, Weill Cornell
Medical College and Co-Principal Investigator of Corbus’ Phase 3
RESOLVE-1 study in systemic sclerosisAbstract
Number: OP0171
Poster
Title: Long-term Safety and Efficacy
of Lenabasum during 3 Years in an Open-Label Extension (OLE) of a
Phase 2 Study of Lenabasum in Refractory Skin Disease in
Dermatomyositis (DM)Session: Scleroderma,
myositis and related syndromesDate: Saturday,
June 5, 2021 Presentation Time: 10:30 a.m. -
10:36 a.m. CEST (4:30 a.m. – 4:36 a.m.
EDT)Presenter: Victoria Werth, M.D., Professor of
Dermatology and Medicine at the University of Pennsylvania Perelman
School of Medicine and Co-Principal Investigator of Corbus' Phase
3 DETERMINE study in
dermatomyositisAbstract Number: POS0315
The abstracts are published in the EULAR 2021
Abstract Archive on the conference website. EULAR presentations are
under embargo until 00:01 GMT+1 on June 2, 2021. Once the
presentations are made public, they will be available on the
Company’s website in the Scientific Conferences section.
About Lenabasum
Lenabasum is a novel, oral, small molecule
designed to provide an alternative to immunosuppressive treatments
for inflammatory or fibrotic diseases. Lenabasum binds to and
activates the cannabinoid receptor type 2 (CB2), which is
preferentially expressed on activated immune cells, to resolve
inflammation and limit fibrosis. Data from animal models and human
clinical studies suggest that lenabasum can reduce expression of
genes and proteins involved in inflammation and fibrosis. In
clinical testing to date, lenabasum has acceptable safety and
tolerability profiles without evidence of immunosuppression.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a
clinical-stage company focused on the development and
commercialization of novel medicines designed to target the
endocannabinoid system. The Company’s lead product candidate,
lenabasum, is a novel, oral, selective cannabinoid receptor type 2
(CB2) agonist designed to provide an alternative to
immunosuppressive medications in the treatment of chronic
inflammatory and fibrotic diseases. Lenabasum is currently being
evaluated in dermatomyositis and systemic lupus erythematosus.
Corbus is also developing a pipeline of other preclinical drug
candidates from its endocannabinoid system platform.
Lenabasum is not approved for the treatment of
any indication. For more information on Corbus’ clinical programs,
please visit here.
For more information, visit
http://www.corbuspharma.com/, and connect with us on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's restructuring,
trial results, product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statement that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management's
current beliefs and assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential,” "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors,
including the potential impact of the recent COVID-19 pandemic and
the potential impact of sustained social distancing efforts, on our
operations, clinical development plans and timelines, which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7745 Email:
ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7749 Email:
mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024